A new sleep aid may offer a safer way to quit benzodiazepines
NCT ID NCT07733414
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether daridorexant, a newer sleep medication that works differently from older drugs, can help people with insomnia safely stop taking benzodiazepine receptor agonists (BZRAs). About 156 adults aged 18 to 70 will gradually replace their current sleep medication with daridorexant over several weeks. The goal is to see if most participants can successfully switch without their insomnia getting worse or experiencing serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daridorexant, a dual orexin receptor antagonist (DORA) taken as a 50 mg tablet nightly
- What this could lead to
- If successful, this could offer a safer, non-addictive alternative for people who need to stop taking older sleep aids like benzodiazepines.
- What could go wrong
- This is a small, open-label study without a placebo group, so results may be less reliable. Daridorexant can cause side effects like drowsiness or headache.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 10053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.